Recor Medical Announces Paradise Ultrasound Renal Denervation System Receives Manufacturing and Marketing Approval in Japan for the Treatment of Resistant Hypertension.
Terumo Corporation is acquiring OrganOx Limited to enhance organ preservation technology and address transplant challenges globally. Acquisition marks Terumo entry into transplant sector.
The nationwide study will assess the safety and efficacy of the technology that combines standard balloon dilation to open the respiratory tract with drug delivery designed to maintain symptom relief.
The AMStent System leverages a decellularized human amniotic membrane (DCAM). New pre-clinical outcomes demonstrating superior results compared to a commercially available synthetic polymer-covered stent were presented at the 2025 American Association for Bronchology and Interventional Pulmonology (AABIP) Annual Meeting.
While Zimmer has been able to maintain the largest market share over the past decade, competition in the knee reconstruction space is no longer limited to pricing or incremental design improvements. It is evolving into a battle of technological sophistication and long-term clinical outcomes.
The company initiated trials for AGENT DCB, a drug-coated coronary balloon approved for use in the U.S. and currently indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.
According to Company, the patent has profound business implications for Inspira and for its ability to dominate a market with a potential size of $20 billion.
The FDA is aware that Boston Scientific is recalling he Carotid WALLSTENT Monorail Endoprosthesis due to a manufacturing defect that created an inner lumen smaller than specifications, causing resistance when withdrawing the stent delivery system.
Pioneering a new category of robotics in healthcare, Mendaera’s Focalist™ System, cleared for precise instrument placement during ultrasound-guided procedures for one of medicine’s most common and critical techniques.
The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation.